Recent discussions by a panel of experts convened by the FDA have highlighted a potential shift in the approach to hormone replacement therapy (HRT) for menopausal women. The panel is urging the removal of existing warnings about the risks associated with these treatments, advocating for updated labeling and increased education for healthcare providers. This move is rooted in a recognition of the benefits that hormone therapy can offer. The meeting aimed to reassess the safety profile of HRT and explore more informed recommendations for its use in managing menopause symptoms.